In vitro activity of SPR719 against Mycobacterium ulcerans,Mycobacterium marinum and Mycobacterium chimaera |
| |
| Authors: | Sacha J. Pidot Jessica L. Porter Troy Lister Timothy P. Stinear |
| |
| Affiliation: | 1. Department of Microbiology and Immunology at the Doherty Institute, University of Melbourne, Melbourne, Australia;2. Spero Therapeutics, Cambridge, Massachusetts, United States of America;Stanford University, UNITED STATES |
| |
| Abstract: | Nontuberculosis mycobacterial (NTM) infections are increasing in prevalence across the world. In many cases, treatment options for these infections are limited. However, there has been progress in recent years in the development of new antimycobacterial drugs. Here, we investigate the in vitro activity of SPR719, a novel aminobenzimidazole antibiotic and the active form of the clinical-stage compound, SPR720, against several isolates of Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. We show that SPR719 is active against these NTM species with a MIC range of 0.125–4 μg/ml and that this compares favorably with the commonly utilized antimycobacterial antibiotics, rifampicin and clarithromycin. Our findings suggest that SPR720 should be further evaluated for the treatment of NTM infections. |
| |
| Keywords: | |
|
|
